Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Humira prior authorization UnitedHealthcare?
UnitedHealthcare is one of the largest health insurers in the U.S., covering millions of members through commercial, Medicare Advantage, and Medicaid plans. In a major January 2025 formulary shift, Optum Rx removed brand Humira from most preferred formularies and positioned Amjevita (adalimumab-atto) as the preferred biosimilar on many UHC commercial plans. Prior authorization is now required for every adalimumab product, brand and biosimilar alike.
UnitedHealthcare Humira Coverage: What Changed in 2025
UnitedHealthcare is one of the largest health insurers in the U.S., covering millions of members through commercial, Medicare Advantage, and Medicaid plans. In the major January 2025 formulary shift, Optum Rx removed brand Humira from most preferred formularies and positioned Amjevita (adalimumab-atto) as the preferred biosimilar on many UHC commercial plans. Several other biosimilars (Hyrimoz, Cyltezo) were also removed from the Optum Rx formulary, narrowing biosimilar options.
Some employer-sponsored plans still retain brand Humira, but PA is required for ALL adalimumab products, brand and biosimilar. The HHS OIG found that 96% of Medicare Part D plans covered at least one Humira biosimilar for 2025.
This matters because patients stable on brand Humira for years are now being moved into new PA submissions to switch to biosimilars. Practices with large autoimmune patient panels faced mass resubmission of 20-50+ PAs in January 2025.
Why Humira Requires Prior Authorization with UHC
Understanding why UHC requires PA for adalimumab helps staff anticipate documentation needs and avoid common submission errors. Humira is FDA-approved for multiple autoimmune conditions: rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, juvenile idiopathic arthritis, ankylosing spondylitis, hidradenitis suppurativa, and uveitis. Due to its cost (brand Humira listed at $6,900+ per month) and the availability of multiple FDA-approved biosimilars since 2023, UHC requires PA to confirm:
- The patient has a confirmed FDA-approved diagnosis
- Previous conventional therapies were tried or are contraindicated
- Step therapy toward the preferred biosimilar has been met (or a medical exception is documented)
- The prescriber is qualified to manage biologic therapy
UHC applies its adalimumab PA Medical Necessity policy whether the drug is billed under the pharmacy benefit (self-administered) or the medical benefit (provider-administered buy-and-bill).
Step-by-Step Humira PA Process with UnitedHealthcare
A complete, accurate first submission is the single most effective way to avoid delays. The five steps below cover the full UHC adalimumab PA process from formulary check to final decision.
Step 1: Verify formulary status and step therapy. Check the patient’s specific UHC plan. Is brand Humira covered, or is a biosimilar preferred? Which biosimilar? Does the plan require step therapy? Log into the UHC provider portal or call Optum Rx at the pharmacy benefits number on the patient’s ID card.
Step 2: Gather clinical documentation. Collect: confirmed diagnosis with ICD-10 code, prior treatment history (conventional DMARDs, other biologics), disease activity score (DAS28, CDAI, HBI as applicable), lab results (ESR, CRP), clinical notes documenting severity and progression, TB screening results, hepatitis B screening, and letter of medical necessity from the prescribing specialist. Building a pre-submission checklist specific to adalimumab PA that the clinical team completes before the PA coordinator touches the case eliminates the back-and-forth that adds days to every submission.
Step 3: Submit the PA request. Use the UHC provider portal, CoverMyMeds, or fax UHC’s adalimumab PA form. Electronic submission through the portal or CoverMyMeds is strongly preferred because it provides a timestamped confirmation and tracks status in real time. Attach ALL documentation with the initial submission.
Step 4: Track and follow up. UHC typically reviews PA requests within 5-10 business days for standard cases. Under CMS-0057-F (effective Jan 2026), payers must respond within 7 calendar days (standard) or 72 hours (urgent). Monitor the portal daily and respond to information requests within 24 hours.
Step 5: Handle the decision. If approved, record the authorization number, approved dates, quantity limits, and set a reauthorization reminder. If denied, review the specific denial reason, and move to appeal. Provider administered adalimumab billed under the medical benefit adds a separate layer of complexity beyond the pharmacy benefit PA process. When a provider administers adalimumab in the office through buy and bill, the PA submission goes through the medical benefit pathway rather than the pharmacy benefit pathway. The medical benefit PA often has different documentation requirements, different submission portals, and different approval timelines than the pharmacy benefit PA for the same drug. Practices that treat patients with both self-administered and provider-administered adalimumab must maintain two parallel PA workflows. Submitting a medical benefit PA through the pharmacy benefit portal or vice versa generates an automatic denial that adds days to the approval timeline.
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
ICD-10 and HCPCS Codes for Humira PA with UHC
Accurate coding is critical for UHC adalimumab PA. A wrong code triggers automatic denial in many systems.
HCPCS code change (January 2025):
- J0139 replaced J0135 for adalimumab injection billing. Use J0139 for ALL new claims
- Q5131 for biosimilar adalimumab-atto (Amjevita)
- Additional biosimilar Q-codes apply to other adalimumab products
Key ICD-10 codes by indication: M06.9 rheumatoid arthritis, K50.x Crohn’s disease, K51.x ulcerative colitis, L40.50 psoriatic arthritis, L40.0 plaque psoriasis, M08.x juvenile idiopathic arthritis, M45.x ankylosing spondylitis, L73.2 hidradenitis suppurativa, and H20.x uveitis.
Matching the ICD-10 code to an FDA-approved indication is essential. Off-label ICD-10 codes will result in automatic denial. When billing under the medical benefit (buy-and-bill), providers must include the correct J-code AND the appropriate ICD-10 code on the claim.
Common Humira Denial Reasons with UHC and How to Appeal
The AMA reports 31% of physicians say PA requests are “often or always denied.” For adalimumab products with UHC, these are the most common denial reasons:
Denial Reason 1: Step therapy not documented (24% of denials). Patient has not tried the preferred biosimilar. Fix: Document prior biosimilar failure, adverse reaction, or clinical reason for exception in the initial PA. If the patient is new to adalimumab, submit the PA for the preferred biosimilar rather than brand Humira.
Denial Reason 2: Incomplete clinical notes (29% of denials). Payer received the request but not all required documentation. Fix: Submit every document from the payer’s criteria checklist with the initial request. Include progress notes, labs, and disease activity scores.
Denial Reason 3: Incorrect ICD coding (18% of denials). ICD-10 code does not match an FDA-approved indication. Fix: Verify diagnosis-specific codes before submission.
Denial Reason 4: Missing lab/imaging evidence (16% of denials). No TB screening, no hepatitis B results, or no disease activity labs. Fix: Upload ESR/CRP, TB test, and hepatitis B screening with every submission.
Denial Reason 5: Eligibility issues (13% of denials). Patient coverage lapsed or plan changed. Fix: Run a real-time eligibility check before submitting PA.
Appeal process: UHC provides a specific denial reason under CMS-0057-F requirements. Request a peer-to-peer review with UHC’s medical director. The AMA reports 81.7% of appealed PA denials are fully or partially overturned, making the appeal effort worthwhile for virtually every adalimumab denial. Submit the written appeal with original documentation plus additional evidence addressing the specific denial reason. Most UHC plans allow 60-180 days for external appeal.
Ranked by frequency, the adalimumab denial causes are: incomplete clinical notes (29%), step therapy not documented (24%), incorrect ICD coding (18%), missing lab or imaging evidence (16%), and eligibility issues (13%). Each one is preventable with a complete first submission and a pre-submission documentation checklist.
Humira Biosimilar Switching: What UHC Providers Need to Know
The biosimilar switch reality for UHC providers comes down to a few practical rules:
- As of 2026, Optum Rx prefers Amjevita on most UHC commercial formularies. Some plans cover Simlandi (adalimumab-ryvk), Idacio (adalimumab-aacf), or unbranded Cyltezo (adalimumab-adbm)
- FDA-approved adalimumab biosimilars are interchangeable with brand Humira. However, payer formulary preferences determine which biosimilar the PA should be submitted for
- Patients switching from brand Humira to a biosimilar need a new PA even if they had an active Humira authorization
- Clinical documentation for biosimilar PA is identical to brand Humira PA: same diagnosis, same disease activity evidence, same step therapy history
- If a patient has an adverse reaction or treatment failure on a biosimilar and needs to switch back to brand Humira, submit a medical exception PA with documented evidence of the biosimilar failure
Practices should maintain a current biosimilar preference sheet for each major PBM and update it at least quarterly as formulary positions shift throughout the year. The administrative burden of tracking biosimilar formulary changes across UHC, Cigna, Aetna, and BCBS plans is substantial. Each PBM may prefer a different adalimumab biosimilar, and those preferences can shift mid-year when the PBM renegotiates rebate contracts with manufacturers. A PA submitted for the wrong biosimilar generates an automatic denial that requires resubmission with the correct product, adding 7-14 days to the approval timeline.
Humira PA in Arizona, Colorado, and Washington Medicaid
Medicaid adalimumab coverage varies significantly by state. Each state maintains its own PDL, PA criteria, and MCO structure.
Arizona (AHCCCS):
- AHCCCS maintains a FFS Formulary with PA requirements for biologic drugs. Formulary changes updated based on P&T Committee meetings (most recent: May 2025)
- AZ Medicaid MCOs (AzCH, Banner, Mercy Care, Molina, UHC Community Plan AZ) each have separate PA portals and biosimilar preferences
- Submit to the correct MCO, not to AHCCCS directly for managed care members
Colorado (Health First Colorado):
- Health First Colorado requires PA for biologic drugs. PA Helpdesk available 24/7 at 888-672-7203 (fax: 833-465-8957)
- HCPF publishes the Colorado Select Drug List with adalimumab product positions
- Colorado Medicaid MCOs maintain their own formularies with potentially different biosimilar preferences than commercial UHC plans
Washington (Apple Health):
- Washington Apple Health requires PA for biologic drugs. CHPW Apple Health formulary changes effective April 1, 2026 include updated biologic coverage
- Washington HCA publishes the Apple Health PDL with biosimilar preferences
- Coordinated Care and other WA MCOs maintain separate PA processes for adalimumab products
Why this matters for providers: A practice treating both UHC commercial and Medicaid patients in the same state faces completely different formulary rules, PA portals, and preferred biosimilars. Submitting to the wrong portal or requesting the wrong biosimilar creates avoidable denials and delays. A rheumatology practice in Phoenix with 40 adalimumab patients split across UHC commercial, AHCCCS Mercy Care, and Medicare Advantage must maintain three separate PA workflows, check three different formulary positions, and submit through three different portals. Each pathway has its own preferred product, its own step therapy sequence, and its own documentation requirements. Staff who treat all three the same way generate denials on two out of three submissions.
Most UHC PA approvals for biologic drugs last 6 to 12 months. Setting calendar reminders 30 days before every biologic authorization expiration date and assigning reauthorization tracking to a specific staff member prevents lapsed authorizations that disrupt patient care.
Why Practices Outsource Humira Prior Authorization
Biologic PA for adalimumab products with UHC is not a quick phone call. It requires: formulary verification across multiple UHC plan types, biosimilar preference identification, step therapy documentation, clinical evidence compilation, electronic submission, tracking, denial management, peer-to-peer coordination, and reauthorization.
The administrative math: A single adalimumab PA submission takes 30-45 minutes when clinical documentation is gathered, the portal is accessed, and files are attached. Denial and appeal adds 1-2 more hours. Multiply that across a rheumatology or GI practice panel with 30-50 adalimumab patients and the workload consumes entire FTEs.
What Staffingly provides:
- Dedicated biologics prior authorization specialists trained on UHC adalimumab policies, biosimilar formulary rules, and state-specific Medicaid programs
- UHC-specific PA handling for both the pharmacy benefit and medical benefit (buy-and-bill) pathways
- Step therapy documentation, ICD-10 and J0139/Q-code verification, and electronic submission through the UHC portal or CoverMyMeds
- Denial management, peer-to-peer coordination, and appeals on the specific denial reason
- Reauthorization tracking ahead of every 6-to-12-month biologic authorization expiration
- SOC 2 Type II, HITRUST, ISO 27001, and HIPAA aligned workflows
Humira prior authorization with UnitedHealthcare follows a specific clinical pathway that changes with formulary updates. Staying current on UHC requirements and submitting complete documentation on the first attempt prevents the back-and-forth that delays patient treatment. The most common reason for Humira PA denial is incomplete step therapy documentation. Practices need to show specific dates, dosages, and documented outcomes for each failed therapy before UHC will approve Humira.
For practices managing high volumes of specialty drug PAs, outsourcing to a dedicated PA team removes this administrative burden. Staffingly’s rheumatology and biologic PA specialists handle the full lifecycle from formulary verification through submission, denial management, and appeal, so your clinical staff can stay focused on patient care.
